154 related articles for article (PubMed ID: 38066013)
1. A novel biomarker of MMP-cleaved cartilage intermediate layer protein-1 is elevated in patients with rheumatoid arthritis, ankylosing spondylitis and osteoarthritis.
Port H; Hausgaard CM; He Y; Maksymowych WP; Wichuk S; Sinkeviciute D; Bay-Jensen AC; Holm Nielsen S
Sci Rep; 2023 Dec; 13(1):21717. PubMed ID: 38066013
[TBL] [Abstract][Full Text] [Related]
2. Up-regulated expression of cartilage intermediate-layer protein and ANK in articular hyaline cartilage from patients with calcium pyrophosphate dihydrate crystal deposition disease.
Hirose J; Ryan LM; Masuda I
Arthritis Rheum; 2002 Dec; 46(12):3218-29. PubMed ID: 12483726
[TBL] [Abstract][Full Text] [Related]
3. Implication of cartilage intermediate layer protein in cartilage destruction in subsets of patients with osteoarthritis and rheumatoid arthritis.
Tsuruha J; Masuko-Hongo K; Kato T; Sakata M; Nakamura H; Nishioka K
Arthritis Rheum; 2001 Apr; 44(4):838-45. PubMed ID: 11315923
[TBL] [Abstract][Full Text] [Related]
4. Cartilage intermediate layer protein 2 (CILP-2) is expressed in articular and meniscal cartilage and down-regulated in experimental osteoarthritis.
Bernardo BC; Belluoccio D; Rowley L; Little CB; Hansen U; Bateman JF
J Biol Chem; 2011 Oct; 286(43):37758-67. PubMed ID: 21880736
[TBL] [Abstract][Full Text] [Related]
5. One of two chondrocyte-expressed isoforms of cartilage intermediate-layer protein functions as an insulin-like growth factor 1 antagonist.
Johnson K; Farley D; Hu SI; Terkeltaub R
Arthritis Rheum; 2003 May; 48(5):1302-14. PubMed ID: 12746903
[TBL] [Abstract][Full Text] [Related]
6. Expression of CILP-2 and DDR2 and ultrastructural changes in the articular cartilage of patients with knee osteoarthritis undergoing total knee arthroplasty: a pilot morphological study.
Torga T; Suutre S; Kisand K; Aunapuu M; Arend A
Med Mol Morphol; 2023 Mar; 56(1):46-57. PubMed ID: 36370214
[TBL] [Abstract][Full Text] [Related]
7. Increased CD40 expression on articular chondrocytes from patients with rheumatoid arthritis: contribution to production of cytokines and matrix metalloproteinases.
Gotoh H; Kawaguchi Y; Harigai M; Hara M; Saito S; Yamaguchi T; Shimada K; Kawamoto M; Tomatsu T; Kamatani N
J Rheumatol; 2004 Aug; 31(8):1506-12. PubMed ID: 15290728
[TBL] [Abstract][Full Text] [Related]
8. Variations in site and levels of expression of chondrocyte nucleotide pyrophosphohydrolase with aging.
Masuda I; Iyama KI; Halligan BD; Barbieri JT; Haas AL; McCarty DJ; Ryan LM
J Bone Miner Res; 2001 May; 16(5):868-75. PubMed ID: 11341331
[TBL] [Abstract][Full Text] [Related]
9. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation.
Fraser A; Fearon U; Billinghurst RC; Ionescu M; Reece R; Barwick T; Emery P; Poole AR; Veale DJ
Arthritis Rheum; 2003 Nov; 48(11):3085-95. PubMed ID: 14613270
[TBL] [Abstract][Full Text] [Related]
10. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
Maksymowych WP; Poole AR; Hiebert L; Webb A; Ionescu M; Lobanok T; King L; Davis JC
J Rheumatol; 2005 Oct; 32(10):1911-7. PubMed ID: 16206346
[TBL] [Abstract][Full Text] [Related]
11. [Expression of dishevelled-2 in cartilage of rheumatoid arthritis and its effect on cartilage destruction].
Liu XZ; Gao Y; Qi K; Zhao DB
Zhonghua Nei Ke Za Zhi; 2018 Sep; 57(9):674-678. PubMed ID: 30180453
[No Abstract] [Full Text] [Related]
12. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints.
Lark MW; Bayne EK; Flanagan J; Harper CF; Hoerrner LA; Hutchinson NI; Singer II; Donatelli SA; Weidner JR; Williams HR; Mumford RA; Lohmander LS
J Clin Invest; 1997 Jul; 100(1):93-106. PubMed ID: 9202061
[TBL] [Abstract][Full Text] [Related]
13. Osteoarthritis and rheumatoid arthritis pannus have similar qualitative metabolic characteristics and pro-inflammatory cytokine response.
Furuzawa-Carballeda J; Macip-Rodríguez PM; Cabral AR
Clin Exp Rheumatol; 2008; 26(4):554-60. PubMed ID: 18799084
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis.
Mahmoud RK; El-Ansary AK; El-Eishi HH; Kamal HM; El-Saeed NH
Ital J Biochem; 2005; 54(3-4):248-57. PubMed ID: 16688934
[TBL] [Abstract][Full Text] [Related]
15. Cartilage intermediate layer protein expression in calcium pyrophosphate dihydrate crystal deposition disease.
Yamakawa K; Iwasaki H; Masuda I; Ohjimi Y; Honda I; Iyama K; Shono E; Naito M; Kikuchi M
J Rheumatol; 2002 Aug; 29(8):1746-53. PubMed ID: 12180739
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional regulation of the cartilage intermediate layer protein (CILP) gene.
Mori M; Nakajima M; Mikami Y; Seki S; Takigawa M; Kubo T; Ikegawa S
Biochem Biophys Res Commun; 2006 Mar; 341(1):121-7. PubMed ID: 16413503
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinase 10 promotion of collagenolysis via procollagenase activation: implications for cartilage degradation in arthritis.
Barksby HE; Milner JM; Patterson AM; Peake NJ; Hui W; Robson T; Lakey R; Middleton J; Cawston TE; Richards CD; Rowan AD
Arthritis Rheum; 2006 Oct; 54(10):3244-53. PubMed ID: 17009259
[TBL] [Abstract][Full Text] [Related]
18. Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis.
Manicourt DH; Poilvache P; Van Egeren A; Devogelaer JP; Lenz ME; Thonar EJ
Arthritis Rheum; 2000 Feb; 43(2):281-8. PubMed ID: 10693867
[TBL] [Abstract][Full Text] [Related]
19. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis.
Maksymowych WP; Landewé R; Conner-Spady B; Dougados M; Mielants H; van der Tempel H; Poole AR; Wang N; van der Heijde D
Arthritis Rheum; 2007 Jun; 56(6):1846-53. PubMed ID: 17530713
[TBL] [Abstract][Full Text] [Related]
20. The active form of MMP-3 is a marker of synovial inflammation and cartilage turnover in inflammatory joint diseases.
Sun S; Bay-Jensen AC; Karsdal MA; Siebuhr AS; Zheng Q; Maksymowych WP; Christiansen TG; Henriksen K
BMC Musculoskelet Disord; 2014 Mar; 15():93. PubMed ID: 24641725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
